

# SECURITIES AND EXCHANGE COMMISSION

## FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2013-01-11** | Period of Report: **2013-01-10**  
SEC Accession No. [0001179110-13-000808](#)

([HTML Version](#) on [secdatabase.com](#))

### REPORTING OWNER

#### **Fust Matthew K**

CIK: **1397266**

Type: **4** | Act: **34** | File No.: **000-28298** | Film No.: **13526407**

Mailing Address  
C/O ONYX  
PHARMACEUTICALS, INC.  
2100 POWELL ST., 12TH  
FLOOR  
EMERYVILLE CA 94608

### ISSUER

#### **ONYX PHARMACEUTICALS INC**

CIK: **1012140** | IRS No.: **943154463** | State of Incorporation: **DE** | Fiscal Year End: **1231**  
SIC: **2836** Biological products, (no diagnostic substances)

Mailing Address	Business Address
249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080	249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 650-266-0000

# FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Expires:	02/28/2011
Estimated average burden hours per response	0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <b>Fust Matthew K</b>			2. Issuer Name and Ticker or Trading Symbol <b>ONYX PHARMACEUTICALS INC</b> [ONXX]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <b>EVP &amp; Chief Financial Officer</b>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <b>01/10/2013</b>					
C/O ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE.			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person		
(Street) <b>SOUTH SAN FRANCISCO, CA 94080</b>								
(City)	(State)	(Zip)						

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D) Price			
Common Stock	01/10/2013		M		7,112	A \$34.48	60,400 <sup>(1)</sup>	D	
Common Stock	01/10/2013		S		6,900 <sup>(2)</sup>	D \$84.41 <sup>(4)</sup>	53,500 <sup>(1)</sup>	D	
Common Stock	01/10/2013		S		3,299 <sup>(2)</sup>	D \$85.83 <sup>(5)</sup>	50,201 <sup>(1)</sup>	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$34.48	01/10/2013		M		7,112		<sup>(3)</sup>	01/05/2019	Common Stock	7,112	\$ 0	63,930	D	

**Explanation of Responses:**

1. Includes 165 shares purchased through the issuer's ESPP on 12/31/12.
2. Shares sold pursuant to a 10b5-1 plan.
3. Twenty-Five percent of the shares subject to the option vest and become exercisable one year from the date of grant and vest and become exercisable at a rate of 1/48th per month thereafter.
4. The shares were sold at prices ranging from \$83.92 to \$84.6901. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
5. The shares were sold at prices ranging from \$85.82 to \$85.84. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

**Signatures**

/s/ Warren DeSouza, Attorney-in-fact

\*\* Signature of Reporting Person

01/14/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**